Donate For Public and Patients Store Search

S052 - Systemic Therapies for Dermatologists: A Comprehensive Review and Update

Monday, March 4; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Evaluate and manage pneumocystis and glucose-induced osteoporosis (GIOP) in immune suppressed patients and recommend vaccines appropriately in patients when on (or starting) immune suppression
  • Recognize and manage adverse effects seen with newer medications for psoriasis, eczema and melanoma
  • Recognize and manage drug-induced autoimmune diseases that present on the skin


We practice in an exciting time with new medications for so many cutaneous disorders. Unfortunately issues and adverse effects arise with these drugs from time to time. In this session we hear how to address pneumocystis, GIOP, and vaccines in the immune suppressed patient as well as adverse effects seen with biologic agents for psoriasis and eczema, new therapies for melanoma, and the drug-induced autoimmune diseases that present in the skin.


  • Fett, Nicole, MD: La Roche-Posay Laboratorie Pharmaceutique – I(Fees); Pfizer Inc. – I(Fees);
  • Garg, Amit, MD: AbbVie – A(H), I(Grants/Research Funding); Asana Biosciences, LLC – A(H); National Psoriasis Foundation – I(Grants/Research Funding); Pfizer Inc. – A(H); UCB – C(H);
  • Haemel, Anna, MD: CSL Behring – Data Safety Monitoring Board(NC);
  • Nunley, Julia R., MD: American Board of Dermatology – B(NC); Springer Science & Business Media – O(H); UpToDate, Inc – O(H); WebMD – O(H);
  • Patel, Anisha, MD: Novartis Pharmaceuticals Corp. – A(Fees);
  • Porter, Martina J, MD: AbbVie – C(Fees), I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); National Psoriasis Foundation – SP(H); Novartis – C(Fees), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); UCB – I(Grants/Research Funding);
  • Shah, Sonal D., MD: no financial relationships exist with commercial interests.
Monday, March 4
9:00 AM
Dr. Garg / Pneumocystis in immune suppression
9:30 AM
Dr. Fett / Managing glucose-induced osteoporosis
10:00 AM
Dr. Porter / Managing ADE from biologics for psoriasis and eczema
10:30 AM
Dr. Patel / Cutanous ADE from biologics for melanoma
11:00 AM
Dr. Shah / Vaccination use during immune suppression
11:30 AM
Dr. Haemel / Cutaneous manifestations of drug-induced autoimmune diseases
Event Details
  • Date
    Monday, March 4
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 207B
  • CME Credits
  • Type
  • Julia R. Nunley, MD, FAAD
  • Amit Garg, MD, FAAD - Handout
  • Anisha Patel, MD, FAAD - Handout
  • Anna Haemel, MD, FAAD
  • Martina J Porter, MD, FAAD
  • Nicole Fett, MD, FAAD - Handout
  • Sonal D. Shah, MD, FAAD